clinical trial · NCT07156578

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

$RYTM →·phase2·enrolling by invitation·n = 25

Hypothalamic ObesityBivamelagon

brief summary

This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.

started

Nov 10, 2025

primary completion

Apr 15, 2028

completion

Apr 15, 2028

last updated

Feb 10, 2026

official title

A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol